Advertisement

The Long-Term Effectiveness and Safety of Cannabidiol-Enriched Oil in Children With Drug-Resistant Epilepsy

  • Michal Tzadok
    Correspondence
    Communications should be addressed to: Dr. Tzadok, Pediatric Neurology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel 5262000.
    Affiliations
    Pediatric Neurology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel

    Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Search for articles by this author
  • Nasrin Hamed
    Affiliations
    Pediatric Neurology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel

    Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Search for articles by this author
  • Gali Heimer
    Affiliations
    Pediatric Neurology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel

    Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Search for articles by this author
  • Efrat Zohar-Dayan
    Affiliations
    Pediatric Neurology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel

    Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Search for articles by this author
  • Shira Rabinowicz
    Affiliations
    Pediatric Neurology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel

    Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Search for articles by this author
  • Bruria Ben Zeev
    Affiliations
    Pediatric Neurology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel

    Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Search for articles by this author

      Abstract

      Background

      Several retrospective studies on pediatric epilepsy reported positive effects of cannabidiol-enriched artisanal cannabis oil and pure cannabidiol oil on seizure reduction.

      Methods

      This is a retrospective study of children and adolescents with refractory epilepsy caused by various etiologies who were treated with artisanal cannabis oil during January 2014 to June 2019, with at least one year follow-up.

      Results

      Of 114 patients, 84 (73.3%) reported some improvement in seizure frequency at some point during treatment. Fifty-one (59%) of the 86 patients who continued treatment for at least one year showed >50% improvement in seizure frequency. Seizure etiology, seizure type, and patients' age and sex were not found to be associated with the response to cannabidiol-enriched cannabis oil. Side effects were minor, and positive effects beyond seizure reduction were noted.

      Conclusions

      Artisanal cannabidiol-enriched cannabis may be an effective and safe long-term treatment for refractory epilepsy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Pediatric Neurology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Friedman D.
        • Devinsky O.
        Cannabinoids in the treatment of epilepsy.
        N Engl J Med. 2015; 373: 1048-1058
        • O'Connell B.K.
        • Gloss D.
        • Devinsky O.
        Cannabinoids in treatment-resistant epilepsy: a review.
        Epilepsy Behav. 2017; 70: 341-348
        • Mechoulam R.
        • Parker L.A.
        The endocannabinoid system and the brain.
        Annu Rev Psychol. 2013; 64: 21-47
        • Todd S.
        • Arnold J.
        Neural correlates of interactions between cannabidiol and Δ9-tetrahydrocannabinol in mice: implications for medical cannabis.
        Br J Pharmacol. 2016; 173: 53-65
        • Englund A.
        • Morrison P.D.
        • Nottage J.
        • et al.
        Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.
        J Psychopharmacol. 2013; 27: 19-27
        • Marsicano G.
        • Goodenough S.
        • Monory K.
        • et al.
        CB1 cannabinoid receptors and on-demand defense against excitotoxicity.
        Science. 2003; 302: 84-88
        • Bih C.I.
        • Chen T.
        • Nunn A.V.
        • Bazelot M.
        • Dallas M.
        • Whalley B.J.
        Molecular targets of cannabidiol in neurological disorders.
        Neurotherapeutics. 2015; 12: 699-730
        • Hill A.
        • Mercier M.
        • Hill T.
        • et al.
        Cannabidivarin is anticonvulsant in mouse and rat.
        Br J Pharmacol. 2012; 167: 1629-1642
        • Hill T.
        • Cascio M.
        • Romano B.
        • et al.
        Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.
        Br J Pharmacol. 2013; 170: 679-692
        • Jones N.A.
        • Hill A.J.
        • Smith I.
        • et al.
        Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.
        J Pharmacol Exp Ther. 2010; 332: 569-577
        • Jones N.A.
        • Glyn S.E.
        • Akiyama S.
        • et al.
        Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures.
        Seizure. 2012; 21: 344-352
        • Jones N.
        • Hill A.
        • Hill T.
        • et al.
        Assessment of the anticonvulsant effects and tolerability profile of cannabidiol: GW pharmaceuticals' preclinical program (I6-5A).
        Neurology. 2016; 86 (:P2.038)
        • Dos Santos R.
        • Hallak J.
        • Leite J.
        • Zuardi A.
        • Crippa J.
        Phytocannabinoids and epilepsy.
        J Clin Pharm Ther. 2015; 40: 135-143
        • Klein B.D.
        • Jacobson C.A.
        • Metcalf C.S.
        • et al.
        Evaluation of cannabidiol in animal seizure models by the epilepsy therapy screening program (ETSP).
        Neurochem Res. 2017; 42: 1939-1948
        • Press C.A.
        • Knupp K.G.
        • Chapman K.E.
        Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy.
        Epilepsy Behav. 2015; 45: 49-52
        • Tzadok M.
        • Uliel-Siboni S.
        • Linder I.
        • et al.
        CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience.
        Seizure. 2016; 35: 41-44
        • Sulak D.
        • Saneto R.
        • Goldstein B.
        The current status of artisanal cannabis for the treatment of epilepsy in the United States.
        Epilepsy Behav. 2017; 70: 328-333
        • Arzimanoglou A.
        • Brandl U.
        • Cross J.H.
        • et al.
        Epilepsy and cannabidiol: a guide to treatment.
        Epileptic Disord. 2020; 22: 1-14
        • Devinsky O.
        • Marsh E.
        • Friedman D.
        • et al.
        Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
        Lancet Neurol. 2016; 15: 270-278
        • Devinsky O.
        • Patel A.D.
        • Thiele E.A.
        • et al.
        Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
        Neurology. 2018; 90: e1204-e1211
        • Devinsky O.
        • Cross J.H.
        • Laux L.
        • et al.
        Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome.
        N Engl J Med. 2017; 376: 2011-2020
        • Thiele E.A.
        • Marsh E.D.
        • French J.A.
        • et al.
        Cannabidiol in patients with seizures associated with lennox-gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
        Lancet. 2018; 391: 1085-1096
        • Devinsky O.
        • Patel A.D.
        • Cross J.H.
        • et al.
        Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome.
        N Engl J Med. 2018; 378: 1888-1897
        • Szaflarski J.P.
        • Bebin E.M.
        • Comi A.M.
        • et al.
        Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results.
        Epilepsia. 2018; 59: 1540-1548
        • Laux L.C.
        • Bebin E.M.
        • Checketts D.
        • et al.
        Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant lennox-gastaut syndrome or dravet syndrome: expanded access program results.
        Epilepsy Res. 2019; 154: 13-20
        • Thiele E.A.
        • Bebin E.M.
        • Bhathal H.
        • et al.
        Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial.
        JAMA Neurol. 2021; 78: 285-292
        • Pamplona F.A.
        • da Silva L.R.
        • Coan A.C.
        Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis.
        Front Neurol. 2018; 9: 759
        • Hussain S.A.
        • Zhou R.
        • Jacobson C.
        • et al.
        Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox–Gastaut syndrome.
        Epilepsy Behav. 2015; 47: 138-141
        • Patel S.
        • Grinspoon R.
        • Fleming B.
        • et al.
        The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.
        Epilepsia. 2021; 62: 1594-1603
        • Uliel-Sibony S.
        • Hausman-Kedem M.
        • Fattal-Valevski A.
        • Kramer U.
        Cannabidiol-enriched oil in children and adults with treatment- resistant epilepsy does tolerance exist?.
        Brain Dev. 2021; 43: P89-P96